Tags

Type your tag names separated by a space and hit enter

Impact of Long-Term and Low-Dose Antibiotic Prophylaxis on Gut Microbiota in Children.
J Urol. 2020 Jul 02 [Online ahead of print]JU

Abstract

PURPOSE

To evaluate the effect of long-term low-dose antibiotic prophylaxis on children's gut microbiota.

MATERIALS AND METHODS

16S ribosomal RNA gene sequencing was conducted using stool samples of 35 infants (median age, 5.2 months; male/female ratio, 17:18) under 3 years old who underwent antibiotic treatment during the acute phase of febrile urinary tract infection (fUTI). Samples were collected at five timepoints: before, during, and at 1-2, 3-4, and 5-6 months after fUTI onset and antibiotic treatment. Continuous antibiotic prophylaxis (CAP) using trimethoprim-sulfamethoxazole (TMP-SMX CAP) was initiated in 23 cases with vesicoureteral reflux (VUR) of grade III or higher (CAP group), and CAP was not performed in the 12 cases without VUR (non-CAP group).

RESULTS

Within two weeks after fUTI treatment initiation, almost all enteric bacteria belonged to the order Lactobacillales, and gut microbiota diversity decreased compared to the pretreatment level (average Shannon index: pre, 2.9; during, 1.4). The diversity recovered within 1-2 months after fUTI onset in both groups; diversity was maintained during the study period in both groups (p = 0.43). Fewer proportion of gut microbiota component belonged to the order Enterobacteriales (p = 0.002) in the CAP group.

CONCLUSIONS

Our results showed that CAP-treated patients had normal gut microbiota diversity, indicating that the effect of TMP-SMX CAP on gut microbiota was insignificant. Furthermore, TMP-SMX CAP might selectively suppress the growth of bacteria belonging to the order Enterobacteriales, such as Escherichia coli and Klebsiella spp., which are the main causative bacteria of fUTI.

Authors+Show Affiliations

Department of Pediatrics, Kansai Medical University, Hirakata, Osaka, Japan.Department of Pediatrics, Kansai Medical University, Hirakata, Osaka, Japan.Department of Pediatrics, Kansai Medical University, Hirakata, Osaka, Japan.Department of Pediatrics, Kansai Medical University, Hirakata, Osaka, Japan.Nakano Children's Hospital, Osaka, Osaka, Japan.Department of Pediatrics, Kansai Medical University, Hirakata, Osaka, Japan.Department of Legal Medicine, Kansai Medical University, Hirakata, Osaka, Japan.Department of Legal Medicine, Kansai Medical University, Hirakata, Osaka, Japan.Nakano Children's Hospital, Osaka, Osaka, Japan.Department of Pediatrics, Kansai Medical University, Hirakata, Osaka, Japan.Department of Pediatrics, Kansai Medical University, Hirakata, Osaka, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32614253

Citation

Akagawa, Yuko, et al. "Impact of Long-Term and Low-Dose Antibiotic Prophylaxis On Gut Microbiota in Children." The Journal of Urology, 2020, pp. 101097JU0000000000001227.
Akagawa Y, Kimata T, Akagawa S, et al. Impact of Long-Term and Low-Dose Antibiotic Prophylaxis on Gut Microbiota in Children. J Urol. 2020.
Akagawa, Y., Kimata, T., Akagawa, S., Yamaguchi, T., Kato, S., Yamanouchi, S., Hashiyada, M., Akane, A., Kino, M., Tsuji, S., & Kaneko, K. (2020). Impact of Long-Term and Low-Dose Antibiotic Prophylaxis on Gut Microbiota in Children. The Journal of Urology, 101097JU0000000000001227. https://doi.org/10.1097/JU.0000000000001227
Akagawa Y, et al. Impact of Long-Term and Low-Dose Antibiotic Prophylaxis On Gut Microbiota in Children. J Urol. 2020 Jul 2;101097JU0000000000001227. PubMed PMID: 32614253.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of Long-Term and Low-Dose Antibiotic Prophylaxis on Gut Microbiota in Children. AU - Akagawa,Yuko, AU - Kimata,Takahisa, AU - Akagawa,Shohei, AU - Yamaguchi,Tadashi, AU - Kato,Shogo, AU - Yamanouchi,Sohsaku, AU - Hashiyada,Masaki, AU - Akane,Atsushi, AU - Kino,Minoru, AU - Tsuji,Shoji, AU - Kaneko,Kazunari, Y1 - 2020/07/02/ PY - 2020/7/3/entrez KW - continuous antibiotic prophylaxis KW - dysbiosis KW - gut microbiota KW - urinary tract infection KW - vesicoureteral reflux SP - 101097JU0000000000001227 EP - 101097JU0000000000001227 JF - The Journal of urology JO - J. Urol. N2 - PURPOSE: To evaluate the effect of long-term low-dose antibiotic prophylaxis on children's gut microbiota. MATERIALS AND METHODS: 16S ribosomal RNA gene sequencing was conducted using stool samples of 35 infants (median age, 5.2 months; male/female ratio, 17:18) under 3 years old who underwent antibiotic treatment during the acute phase of febrile urinary tract infection (fUTI). Samples were collected at five timepoints: before, during, and at 1-2, 3-4, and 5-6 months after fUTI onset and antibiotic treatment. Continuous antibiotic prophylaxis (CAP) using trimethoprim-sulfamethoxazole (TMP-SMX CAP) was initiated in 23 cases with vesicoureteral reflux (VUR) of grade III or higher (CAP group), and CAP was not performed in the 12 cases without VUR (non-CAP group). RESULTS: Within two weeks after fUTI treatment initiation, almost all enteric bacteria belonged to the order Lactobacillales, and gut microbiota diversity decreased compared to the pretreatment level (average Shannon index: pre, 2.9; during, 1.4). The diversity recovered within 1-2 months after fUTI onset in both groups; diversity was maintained during the study period in both groups (p = 0.43). Fewer proportion of gut microbiota component belonged to the order Enterobacteriales (p = 0.002) in the CAP group. CONCLUSIONS: Our results showed that CAP-treated patients had normal gut microbiota diversity, indicating that the effect of TMP-SMX CAP on gut microbiota was insignificant. Furthermore, TMP-SMX CAP might selectively suppress the growth of bacteria belonging to the order Enterobacteriales, such as Escherichia coli and Klebsiella spp., which are the main causative bacteria of fUTI. SN - 1527-3792 UR - https://www.unboundmedicine.com/medline/citation/32614253/Impact_of_Long-Term_and_Low-Dose_Antibiotic_Prophylaxis_on_Gut_Microbiota_in_Children L2 - https://www.jurology.com/doi/10.1097/JU.0000000000001227?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.